Emilie Masto

Title: Emilie Masto: Innovator in Pharmaceutical Science

Introduction

Emilie Masto, a pioneering inventor based in Swindon, GB, has made significant strides in the field of pharmaceutical science. With a focus on innovative drug delivery systems, Emilie has developed a patented solution that addresses critical healthcare needs, particularly in the realm of vaginal delivery.

Latest Patents

Emilie Masto holds a patent for "Lyophilized pharmaceutical compositions for vaginal delivery." This groundbreaking invention discloses a solid lyophilized vaginal dosage form that includes an effective amount of at least one active ingredient, a crystalline structure forming agent, and a polymeric mucoadhesive matrix forming agent. The dosage form is designed to maintain a pH of about 4.0 to 5.0 and can disintegrate within 120 seconds upon contact with vaginal mucosa, effectively delivering the active ingredient. This innovation presents a promising advancement in pharmaceutical formulations aimed at improving patient compliance and therapeutic effectiveness.

Career Highlights

Emilie works at Catalent UK Swindon Zydis Limited, where her contributions to pharmaceutical development are valued highly. Her dedication to innovative therapies has been instrumental in the company’s mission to provide advanced drug delivery solutions. Emilie's work not only exemplifies her expertise but also showcases her commitment to enhancing healthcare outcomes through technological advancement.

Collaborations

In her role at Catalent, Emilie collaborates with talented colleagues such as Lisa Garrett and Niamh Barrat. Together, they work on developing cutting-edge pharmaceutical products designed to meet the needs of patients and healthcare providers alike. This collaborative environment fosters innovation, enabling Emilie to further refine her expertise and drive forward impactful projects.

Conclusion

Emilie Masto stands out as a notable figure in the domain of pharmaceutical innovations, with her patent exemplifying the exciting possibilities within the field. Her work at Catalent UK Swindon Zydis Limited not only adds to her professional achievements but also contributes to the broader conversation on advancing drug delivery methods. As the healthcare landscape continues to evolve, Emilie’s contributions will undoubtedly play a vital role in shaping future therapies.